MLICM
AMRX icon

Metropolitan Life Insurance Company (MetLife)’s Amneal Pharmaceuticals AMRX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,637
Closed -$34.2K – 128
2024
Q1 		$34.2K Sell
5,637
-1,243
-18% -$7.01K ﹤0.01% 1591
2023
Q4 		$41.8K Hold
6,880
– – ﹤0.01% 1544
2023
Q3 		$29K Buy
6,880
+1,143
+20% +$4.26K ﹤0.01% 1699
2023
Q2 		$17.8K Hold
5,737
– – ﹤0.01% 1996
2023
Q1 		$7.97K Sell
5,737
-554
-9% -$1.1K ﹤0.01% 2226
2022
Q4 		$12.5K Hold
6,291
– – ﹤0.01% 2210
2022
Q3 		$12.7K Buy
6,291
+3,311
+111% +$9.28K ﹤0.01% 2222
2022
Q2 		$9.48K Sell
2,980
-3,369
-53% -$12.2K ﹤0.01% 2315
2022
Q1 		$26.5K Sell
6,349
-13,762
-68% -$60.9K ﹤0.01% 1957
2021
Q4 		$96.3K Sell
20,111
-4,448
-18% -$22.2K ﹤0.01% 2511
2021
Q3 		$131K Sell
24,559
-9,436
-28% -$47.5K ﹤0.01% 2365
2021
Q2 		$174K Buy
33,995
+5,361
+19% +$30.5K ﹤0.01% 2251
2021
Q1 		$193K Buy
28,634
+911
+3% +$5.05K ﹤0.01% 2042
2020
Q4 		$127K Sell
27,723
-3,779
-12% -$16.7K ﹤0.01% 2230
2020
Q3 		$122K Sell
31,502
-5,594
-15% -$23.9K ﹤0.01% 2102
2020
Q2 		$177K Sell
37,096
-1,286
-3% -$5.3K ﹤0.01% 1883
2020
Q1 		$134K Sell
38,382
-1,143
-3% -$4.84K ﹤0.01% 1848
2019
Q4 		$191K Buy
39,525
+20,066
+103% +$69.8K ﹤0.01% 1964
2019
Q3 		$56.4K Sell
19,459
-9,168
-32% -$32K ﹤0.01% 2487
2019
Q2 		$205K Hold
28,627
– – ﹤0.01% 1875
2019
Q1 		$406K Hold
28,627
– – 0.01% 1433
2018
Q4 		$387K Hold
28,627
– – 0.01% 1367
2018
Q3 		$635K Buy
+28,627
New +$602K 0.01% 1205

Other funds holding AMRX

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s AMRX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Amneal Pharmaceuticals (AMRX) in Q2 2024, closing a stake of 5,637 shares — an estimated $34.2K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in AMRX in Q3 2018 and held it in 23 quarters. The position peaked at $635K in Q3 2018. 181 funds tracked by Wall St. Rank hold AMRX as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Amneal Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 5,637 Amneal Pharmaceuticals shares in Q2 2024, an estimated $34.2K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Amneal Pharmaceuticals in Q3 2018 and held it in 23 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Amneal Pharmaceuticals position peaked at $635K in Q3 2018.
  • 181 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.